Baxter’s Brazilian haemophilia treatment deal to add $200m annual sales
This article was originally published in Clinica
Executive Summary
Baxter International will be exclusive supplier of recombinant factor VIII (rFVIII) therapy to Brazil's haemophilia patients for the next decade, after signing a deal that spans 20 years in total with the country's state-owned blood products and biotechnology firm Hemobr�s. Baxter expects peak annual sales of over $200 million from the agreement.